Progress in the development of nucleic acid therapeutics.

Handb Exp Pharmacol

Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, 421 Curie Blvd, Philadelphia PA, 19104, USA.

Published: April 2006

Abnormal gene expression is a hallmark of many diseases. Gene-specific downregulation of aberrant genes could be useful therapeutically and potentially less toxic than conventional therapies due its specificity. Over the years, many strategies have been proposed for silencing gene expression in a gene-specific manner. Three major approaches are antisense oligonucleotides (AS-ONs), ribozymes/DNAzymes, and RNA interference (RNAi). In this brief review, we will discuss the successes and shortcomings of these three gene-silencing methods, and the approaches being taken to improve the effectiveness of antisense molecules. We will also provide an overview of some of the clinical applications of antisense therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/3-540-27262-3_9DOI Listing

Publication Analysis

Top Keywords

gene expression
8
progress development
4
development nucleic
4
nucleic acid
4
acid therapeutics
4
therapeutics abnormal
4
abnormal gene
4
expression hallmark
4
hallmark diseases
4
diseases gene-specific
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!